カテゴリ： GlobalData, アメリカ, 企業調査

Dynavax Technologies Corp (DVAX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Dynavax Technologies Corp (DVAX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10124
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：58
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Dynavax Technologies Corp (Dynavax), formerly Double Helix Corp, is a clinical-stage biopharmaceutical company that develops product candidates for the prevention of infectious and inflammatory disease. The company’s only marketed product Heplisav-B is an adult vaccine for hepatitis B. Its pipeline includes AZD1419, a drug for the treatment of asthma; DV281, an agonist which focuses on lung tumors and lung metastases; and SD-101, an agonist focusing on immune response to various cancers. Dynavax’s pre-clinical pipeline encompasses DV230F for liver tumors, DV1001 for multiple malignancies. The company develops immunotherapies based on toll-like receptor technology for the treatment and prevention of infectious and inflammatory diseases and cancer. It has subsidiary in Germany. Dynavax is headquartered in Berkeley, California, the US.

Dynavax Technologies Corp (DVAX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dynavax Technologies Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Dynavax Technologies Corp, Medical Devices Deals, 2012 to YTD 2018 10
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Dynavax Raises USD40 Million from Hercules Technology 12
Double Helix Raises USD0.048 Million in Seed Financing 13
Partnerships 14
Dynavax Technologies and Quantum Leap Healthcare Collaborative Enter into Agreement 14
Vectura Enters into Agreement with Dynavax Technologies 15
Blirt Enters into Agreement with Rhein Biotech for Cancer Vaccine 16
Equity Offering 17
Dynavax Technologies Plans to Raise USD150 Million in Public Offering of Shares 17
Dynavax Technologies Raises USD86.2 Million in Public Offering of Shares 18
Dynavax Technologies Raises USD143.8 Million in Public Offering of Shares 20
Dynavax Technologies Completes Public Offering Of Shares For US$85.5 Million 22
Dynavax Technologies Completes Public Offering Of Preferred Stock For US$46.7 Million 23
Dynavax Technologies Announces Public Offering Of Shares For US$50 Million 24
Dynavax Technologies Completes Public Offering Of Common Stock For US$74 Million 25
Debt Offering 26
Dynavax Technologies to Raise USD100 Million in Private Placement of Notes 26
Acquisition 27
McCann Health Acquires Double Helix, Provider Of Healthcare Consultancy Services, For US$78 Million 27
Dynavax Technologies Corp – Key Competitors 28
Dynavax Technologies Corp – Key Employees 29
Dynavax Technologies Corp – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 05, 2018: Dynavax reports third quarter 2018 financial results, progress on HEPLISAV-B launch, and updated SD-101 data in three patient populations 31
Aug 06, 2018: Dynavax reports second quarter 2018 financial results 33
May 08, 2018: Dynavax Announces First Quarter 2018 Financial Results 34
Mar 08, 2018: Dynavax Reports Fourth Quarter and Year End 2017 Financial Results 35
Nov 03, 2017: Dynavax Reports Third Quarter 2017 Financial Results 36
Aug 02, 2017: Dynavax Reports Second Quarter 2017 Financial Results 37
May 08, 2017: Dynavax Reports First Quarter 2017 Financial Results 38
Mar 13, 2017: Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update 39
Corporate Communications 41
Jun 28, 2018: Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs 41
Mar 02, 2018: Stanley A. Plotkin, M.D. Steps Down from Board of Dynavax Technologies 43
Product News 44
06/02/2017: Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA (pembrolizumab) Highlighting an ORR in 7 out of 7 Patients Naive to an Anti-PD-1 or Anti-PD-L1 Therapy 44
05/19/2017: Dynavax to Present Data on SD-101 in Combination with KEYTRUDA at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting 45
05/16/2018: Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting 46
04/17/2018: Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting 47
04/16/2018: Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck 48
03/20/2017: Dynavax to Present Data on SD-101 at the 2017 American Association for Cancer Research Annual Meeting 50
03/20/2017: Dynavax to Present Data on TLR9-Adjuvanted Nanoparticle Cancer Vaccine at the 2017 American Association for Cancer Research Annual Meeting 51
03/20/2017: Dynavax to Present DV-281 at the 2017 American Association for Cancer Research Annual Meeting 52
03/15/2018: Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA for Presentation at the 2018 American Association for Cancer Research Annual Meeting 53
03/06/2017: Dynavax Presents Promising Clinical Data from Lead Immuno-Oncology Candidate, SD-101, at the International Congress on Targeted Anticancer Therapies 54
01/05/2017: Dynavax Provides Update on SD-101 Oncology Program 55
Clinical Trials 56
Oct 19, 2017: Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy 56
Jan 05, 2017: Dynavax Provides Update on DV-281 Oncology Program 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dynavax Technologies Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dynavax Technologies Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Dynavax Technologies Corp, Medical Devices Deals, 2012 to YTD 2018 10
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Dynavax Raises USD40 Million from Hercules Technology 12
Double Helix Raises USD0.048 Million in Seed Financing 13
Dynavax Technologies and Quantum Leap Healthcare Collaborative Enter into Agreement 14
Vectura Enters into Agreement with Dynavax Technologies 15
Blirt Enters into Agreement with Rhein Biotech for Cancer Vaccine 16
Dynavax Technologies Plans to Raise USD150 Million in Public Offering of Shares 17
Dynavax Technologies Raises USD86.2 Million in Public Offering of Shares 18
Dynavax Technologies Raises USD143.8 Million in Public Offering of Shares 20
Dynavax Technologies Completes Public Offering Of Shares For US$85.5 Million 22
Dynavax Technologies Completes Public Offering Of Preferred Stock For US$46.7 Million 23
Dynavax Technologies Announces Public Offering Of Shares For US$50 Million 24
Dynavax Technologies Completes Public Offering Of Common Stock For US$74 Million 25
Dynavax Technologies to Raise USD100 Million in Private Placement of Notes 26
McCann Health Acquires Double Helix, Provider Of Healthcare Consultancy Services, For US$78 Million 27
Dynavax Technologies Corp, Key Competitors 28
Dynavax Technologies Corp, Key Employees 29
Dynavax Technologies Corp, Subsidiaries 30

List of Figures
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Dynavax Technologies Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Dynavax Technologies Corp (DVAX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Specialised Therapeutics Australia Pty Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Specialised Therapeutics Australia Pty Ltd (STA) is a biopharmaceutical company that develops and commercializes medicines in various therapeutic areas. The company’s products include abraxane, gliolan, oncotype dx, iclusig, oncotype dx prostate and aloxi. Its pipeline products comprise anam …
  • Svenska Cellulosa Aktiebolaget：企業の戦略・SWOT・財務情報
    Svenska Cellulosa Aktiebolaget - Strategy, SWOT and Corporate Finance Report Summary Svenska Cellulosa Aktiebolaget - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Isetan Mitsukoshi Holdings Ltd.：戦略・SWOT・企業財務分析
    Isetan Mitsukoshi Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Isetan Mitsukoshi Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Forward Industries, Inc. (FORD)：企業の財務・戦略的SWOT分析
    Forward Industries, Inc. (FORD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Rollins Inc (ROL)：企業の財務・戦略的SWOT分析
    Summary Rollins Inc (Rollins) is a consumer and commercial service provider that provides essential pest control services and protection against termite damage, rodents and insects. The company provides services through its international franchises. It also offers customized services to its clients …
  • NuVasive Inc (NUVA)：製品パイプライン分析
    Summary NuVasive Inc (NuVasive) is a medical device company that provides minimally invasive, procedurally-integrated spine solutions. The company principally provides Maximum Access Surgery (MAS), a minimally-disruptive surgical platform. MAS platform enables surgeons to perform a range of minimall …
  • Dr. Reddy’s Laboratories Limited：企業の戦略・SWOT・財務情報
    Dr. Reddy's Laboratories Limited - Strategy, SWOT and Corporate Finance Report Summary Dr. Reddy's Laboratories Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Altimmune Inc-製薬・医療分野：企業M&A・提携分析
    Summary Altimmune Inc (Altimmune), formerly Vaxin Inc is a biotechnology company that develops vaccines and other biological products. The company's products include novel vaccine delivery platforms, immunotherapeutic products, intranasally administered recombinant influenza vaccine, traditional inf …
  • Genisphere LLC-製薬・医療分野：企業M&A・提携分析
    Summary Genisphere LLC (Genisphere) is a nanotechnology company which provides DNA-based targeted drug delivery solutions. The company utilizes its proprietary 3DNA platform which enables the application in gene delivery, biologics, small molecules, and RNAi therapuetics. It develops pipeline produc …
  • San Juan Basin Royalty Trust (SJT)：企業の財務・戦略的SWOT分析
    Summary San Juan Basin Royalty Trust (SJT) operates as a trust that has overriding royalty interest divided out of Southland Royalty's oil and gas leasehold and royalty interest in the San Juan Basin of northwestern New Mexico. The trust’s underlying properties include royalty interests, overriding …
  • Franz Haniel & Cie. GmbH：企業の戦略・SWOT・財務分析
    Franz Haniel & Cie. GmbH - Strategy, SWOT and Corporate Finance Report Summary Franz Haniel & Cie. GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Cenovus Energy Inc (CVE)：石油・ガス：M&Aディール及び事業提携情報
    Summary Cenovus Energy Inc (Cenovus Energy) is an integrated energy company, which explores, develops, produces and markets crude oil, natural gas liquids (NGLs) and natural gas. Cenovus Energy produces natural gas and oil through conventional and oil sands reserves in Athabasca region of northeaste …
  • Mitsui O.S.K. Lines, Ltd.：企業の戦略・SWOT・財務分析
    Mitsui O.S.K. Lines, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsui O.S.K. Lines, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Neusoft Corporation (600718)：企業の財務・戦略的SWOT分析
    Neusoft Corporation (600718) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Adams Resources & Energy, Inc.：企業の戦略・SWOT・財務分析
    Adams Resources & Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Adams Resources & Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Johnson Controls International Plc (JCI)：電力：M&Aディール及び事業提携情報
    Summary Johnson Controls International Plc (Johnson Controls) is a diversified technology and multi industrial company. It creates intelligent buildings, integrated infrastructure, efficient energy solutions, and next generation transportation systems. The company provides HVAC equipment, HVAC contr …
  • Novo Nordisk AS (NOVO B)：企業の財務・戦略的SWOT分析
    Novo Nordisk AS (NOVO B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tel-Instrument Electronics Corp.：企業の戦略・SWOT・財務情報
    Tel-Instrument Electronics Corp. - Strategy, SWOT and Corporate Finance Report Summary Tel-Instrument Electronics Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Acorn Energy Inc (ACFN)：企業の財務・戦略的SWOT分析
    Acorn Energy Inc (ACFN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Gannett Co., Inc.：戦略・SWOT・企業財務分析
    Gannett Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Gannett Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆